Abstracts tagged "cannabinoid"

Abstract Number: 879 • 2019 ACR/ARP Annual Meeting
Evaluation of Marijuana and Cannabidiol Use in the Rheumatologic Population from a Patient and Clinician Perspective: A Survey-Based Study
Heather Goodwin ¹, Ali Porter¹, Melinda Edwards ¹ and Bonita Libman ¹, ¹The University of Vermont Medical Center, Burlington, VT
Background/Purpose: To evaluate use of marijuana (MJ) and cannabidiol (CBD) as described by rheumatology patients at an academic medical center in Vermont, and to describe beliefs and…
Abstract Number: 2929 • 2019 ACR/ARP Annual Meeting
Cannabis Use Among Patients in a Large US Rheumatic Disease Registry
Kristin Wipfler ¹, Teresa Simon², Patricia Katz ³, Frederick Wolfe ⁴ and Kaleb Michaud ⁵, ¹FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS, ²Bristol-Myers Squibb*, Princeton, NJ, ³University of California, San Francisco, san francisco, CA, ⁴FORWARD, The National Databank for Rheumatic Diseases & University of Nebraska Medical Center, Wichita, KS, ⁵FORWARD, The National Databank for Rheumatic Diseases and University of Nebraska Medical Center, Wichita, KS
Background/Purpose: Legalization of cannabis use is rapidly increasing worldwide, raising the need to evaluate trends and medical implications. A systematic literature review showed inconsistent results…
Abstract Number: 1068 • 2018 ACR/ARHP Annual Meeting
Characterization of the Role of Endocannabinoid System Using Jwh-133, a Selective Cannabinoid CB2 Receptor Agonist, in IL-1β-Induced Inflammation in Human Rheumatoid Arthritis Synovial Fibroblasts
Sabrina Fechtner¹, Anil K. Singh¹ and Salahuddin Ahmed^1,2, ¹Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA, ²Division of Rheumatology, University of Washington, Division of Rheumatology, School of Medicine, Seattle, WA
Background/Purpose: The endocannabinoid system (ECS) is comprised of two evolutionary conserved cannabinoid receptors 1 and 2 (CB1 and CB2) which participate in pain management through…
Abstract Number: 1715 • 2018 ACR/ARHP Annual Meeting
Safety and Efficacy of Lenabasum in an Open-Label Extension of a Phase 2 Study in Diffuse Cutaneous Systemic Sclerosis Subjects
Robert F. Spiera¹, Laura K. Hummers², Lorinda Chung³, Tracy M. Frech⁴, Robyn T. Domsic⁵, Vivien Hsu⁶, Daniel E. Furst⁷, Jessica K. Gordon¹, Maureen D. Mayes⁸, Robert W. Simms⁹, Elizabeth Lee¹⁰, Scott Constantine¹⁰ and Barbara White¹⁰, ¹Hospital for Special Surgery, New York, NY, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ⁴Division of Rheumatology, University of Utah, Salt Lake City, UT, ⁵Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁶Rheumatology, Robert Wood Johnson Medical School, New Brunswick, NJ, ⁷Pacific Arthritis Associates, Los Angeles; University of California, Los Angeles; University of Washington, Seattle; University of Florence, Italy, Los Angeles, CA, ⁸Rheumatology, University of Texas McGovern Medical School, Houston, TX, ⁹Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁰Corbus Pharmaceuticals, Inc., Norwood, MA
Background/Purpose: Lenabasum is a synthetic, non-immunosuppressive, selective cannabinoid receptor type 2 agonist that activates resolution of innate immune responses. Lenabasum had acceptable safety and tolerability,…
Abstract Number: 7L • 2017 ACR/ARHP Annual Meeting
A Phase 2 Study of Safety and Efficacy of Anabasum (JBT-101), a Cannabinoid Receptor Type 2 Agonist, in Refractory Skin-Predominant Dermatomyositis
Victoria P. Werth¹, Emily Hejazi², Sandra M. Pena¹, Jessica S. Haber³, Joyce Okawa¹, Rui Feng⁴, Kirubel Gabre², Josef Concha², Caitlin Cornwall⁵, Nancy Dgetluck⁶, Scott Constantine⁵ and Barbara White⁵, ¹Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Department of Dermatology, University of Pennsylvania, Philadelphia, PA, ⁴Department of Biostatistics and Epidemiology at the Hospital of the University of Pennsylvania, Philadelphia, PA, ⁵Corbus Pharmaceuticals, Inc., Norwood, MA, ⁶Biostatistics, Corbus Pharmaceuticals, Inc., Norwood, MA

Background/Purpose: Effective treatment options are limited for refractory skin disease in dermatomyositis (DM). Anabasum is a non-immunosuppressive, synthetic, oral preferential CB2 agonist that triggers resolution…
Abstract Number: 976 • 2017 ACR/ARHP Annual Meeting
Cannabinoid Receptor 2 Agonist (JWH-015) Inhibits Interleukin-1β-Induced Inflammation in Rheumatoid Arthritis Synovial Fibroblasts
Sabrina Fechtner and Salahuddin Ahmed, Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by activated synovial fibroblasts in which pro-inflammatory cytokine interleukin-1β (IL-1β) mediates inflammation. The endocannabinoid system…
Abstract Number: 1707 • 2017 ACR/ARHP Annual Meeting
Effect of Anabasum (JBT-101) on Gene Expression in Skin Biopsies from Subjects with Diffuse Cutaneous Systemic Sclerosis (dcSSc) and the Relationship of Baseline Molecular Subsets to Clinical Benefit in the Phase 2 Trial
Viktor Martyanov¹, Yolanda Nesbeth², Guoshuai Cai¹, Tammara A. Wood¹, Jake Reder², Scott Constantine³, Barbara White³, Robert F. Spiera⁴ and Michael L. Whitfield¹, ¹Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ²Celdara Medical, LLC, Lebanon, NH, ³Corbus Pharmaceuticals, Inc., Norwood, MA, ⁴Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: Anabasum (JBT-101) is a non-immunosuppressive, synthetic, CB2 agonist that resolves inflammation and fibrosis in animal models of SSc and reduces TGF-β and collagen production…
Abstract Number: 2884 • 2017 ACR/ARHP Annual Meeting
A Phase 2 Study of Safety and Efficacy of Anabasum (JBT-101), a Cannabinoid Receptor Type 2 Agonist, in Diffuse Cutaneous Systemic Sclerosis
Robert F. Spiera¹, Laura K. Hummers², Lorinda Chung³, Tracy M. Frech⁴, Robyn T. Domsic⁵, Vivien Hsu⁶, Daniel E. Furst⁷, Jessica K. Gordon¹, Maureen D. Mayes⁸, Robert W. Simms⁹, Scott Constantine¹⁰ and Barbara White¹⁰, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Medical and Rheumatology, Johns Hopkins University, Baltimore, MD, ³Rheumatology, Stanford University Medical Center, Palo Alto, CA, ⁴Division of Rheumatology, University of Utah, Salt Lake City, UT, ⁵Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁶Rheumatology, Robert Wood Johnson University Scleroderma Program, New Brunswick, NJ, ⁷David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁸University of Texas McGovern Medical School, Houston, TX, ⁹Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁰Corbus Pharmaceuticals, Inc., Norwood, MA
Background/Purpose: Systemic sclerosis (SSc) is characterized in part by chronic activation of the innate immune system with fibrosis. Anabasum is a non-immunosuppressive, synthetic, orally administered…
Abstract Number: 725 • 2017 ACR/ARHP Annual Meeting
Safety and Efficacy of Anabasum (JBT-101) in Diffuse Cutaneous Systemic Sclerosis (dcSSc) Subjects Treated in an Open-Label Extension of Trial JBT101-SSc-001
Robert F. Spiera¹, Laura K. Hummers², Lorinda Chung³, Tracy M. Frech⁴, Robyn T. Domsic⁵, Vivien Hsu⁶, Daniel E. Furst⁷, Jessica K. Gordon¹, Maureen D. Mayes⁸, Robert W. Simms⁹, Scott Constantine¹⁰ and Barbara White¹⁰, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Medical and Rheumatology, Johns Hopkins University, Baltimore, MD, ³Rheumatology, Stanford University Medical Center, Palo Alto, CA, ⁴Division of Rheumatology, University of Utah, Salt Lake City, UT, ⁵Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁶Rheumatology, Robert Wood Johnson University Scleroderma Program, New Brunswick, NJ, ⁷David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁸Internal Medicine/Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ⁹Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁰Corbus Pharmaceuticals, Inc., Norwood, MA
Background/Purpose: Anabasum (JBT-101) is a selective cannabinoid receptor type 2 agonist that activates resolution of innate immune responses and limits fibrosis in animal models of…
Abstract Number: 738 • 2017 ACR/ARHP Annual Meeting
Prospective Validation of the Systemic Sclerosis Skin Symptoms Patient-Reported Outcome (SSPRO) in a Phase 2 Trial of Anabasum (JBT-101) in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Ada Man¹, Nancy Dgetluck² and Barbara White³, ¹Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ²Biostatistics, Corbus Pharmaceuticals, Norwood, MA, ³Corbus Pharmaceuticals, Inc., Norwood, MA
Background/Purpose: Skin thickening is the defining manifestation of dcSSc. A dcSSc patient’s assessment of their skin involvement can provide information about how that patient feels…
Abstract Number: 53 • 2016 ACR/ARHP Annual Meeting
Efficacy of Cannabis Flos in Patients with Fibromyalgia: A Monocentric Observational Study
Maria Chiara Gerardi¹, Alberto Batticciotto², Rossella Talotta¹, Maria Chiara Ditto¹, Fabiola Atzeni² and Piercarlo Sarzi-Puttini¹, ¹Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milan, Italy, ²Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milano, Italy
Efficacy of Cannabis flos in patients with fibromyalgia: a monocentric observational study Background/Purpose: Fibromyalgia (FM) is a syndrome characterized by chronic widespread pain, fatigue,…
Abstract Number: 2789 • 2014 ACR/ARHP Annual Meeting
Medical Marijuana Related Outcomes in Patients with Systemic Lupus Erythematosis
Basmah Jalil¹, Wilmer Sibbitt Jr.², Romy Cabacangun³, Clifford Qualls⁴, Arthur Bankhurst⁵ and Roderick Fields⁶, ¹Internal Medicine/Rheumatology, University of New Mexico, Albuquerque, NM, ²Internal Medicine/Rheumatology, University of New Mexico HSC, Albuquerque, NM, ³Rheumatology, UNM, Albuquerque, NM, ⁴Biostatistics, UNM, Albuquerque, NM, ⁵Rheum/ MSC 105550, University of NM Med Ctr, Albuquerque, NM, ⁶Internal Medicine/ Rheumatology, University of New Mexico School of Medicine, Albuquerque, NM
Background/Purpose Medical cannabis is used extensively in the United States, usually in the form of smoked marijuana. There is growing research regarding the immunomodulatory effects…
Abstract Number: 1029 • 2014 ACR/ARHP Annual Meeting
Anandamide and Related Eicosanoids Decrease the Production of Pro-Inflammatory Cytokines in Synovial Fibroblasts By a COX-2 Dependent Mechanism: Involvement of Calcium and TRP Channels
Torsten Lowin¹, Tanja Späth², Angelika Graeber¹ and Rainer Straub³, ¹Department of Internal Medicine I, Laboratory of Exp. Rheumatology and Neuroendocrino-Immunology, University Hospital of Regensburg, Regensburg, Germany, ²Department of Internal Medicine I, Laboratory of Exp. Rheumatology and Neuroendocrino-Immunology, Regensburg, Germany, ³Internal Medicine, University Hospital Regensburg, Regensburg, Germany
Background/Purpose: Endocannabinoids are immunomodulatory lipid compounds that act on cannabinoid receptors type 1 and 2 but also on transient receptor potential (TRP) channels. Their action…
Abstract Number: 264 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of Cannabinoid Treatments in the Rheumatic Diseases: A Systematic Review of Randomized Controlled Trials
Tara Landry¹, Mary-Ann Fitzcharles², Peter A. Ste-Marie³ and Yoram Shir³, ¹Montreal General Hospital Medical Library, Mcgill University Health Centre, Montreal, QC, Canada, ²Rheumatology & Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada, ³Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: The endocannabinoid system functions to maintain homeostasis in the human body and thereby has effects on modulation of pain and inflammation. Cannabinoid preparations are…
Abstract Number: 122 • 2013 ACR/ARHP Annual Meeting
Rheumatologists Lack Confidence in Their Knowledge of Cannabinoid Molecules and Use in the Management of Rheumatic Disease Patients: Analysis of a Needs Assessment
Mary-Ann Fitzcharles¹, Peter A. Ste-Marie², Daniel J. Clauw³, Shahin Jamal⁴, Jacob Karsh⁵, Sharon Leclercq⁶, Jason J. McDougall⁷, Yoram Shir², Kamran Shojania⁸ and Zach Walsh⁹, ¹Rheumatology & Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada, ²Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada, ³Anesthesiology/Internal Medicine (Rheum), University of Michigan, Ann Arbor, MI, ⁴Department of Rheumatology, University of British Columbia, Vancouver, BC, Canada, ⁵Ottawa Hosp Riverside, Ottawa, ON, Canada, ⁶Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ⁷Departments of Pharmacology and Anaesthesia, Dalhousie University, Halifax, NS, Canada, ⁸Rheumatology, University of British Columbia, Vancouver, BC, Canada, ⁹Department of Psychology, University of British Columbia, Kelowna, BC, Canada
Background/Purpose: The pharmacologic treatment of chronic rheumatic pain is often sub-optimal, leading patients to seek alternate treatments. Although herbal cannabis (marihuana) has had medicinal use…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].